Moderatley to Highly Exuding Venous Leg Ulcers
Conditions
Keywords
dressing for venous leg ulcers
Brief summary
This is a clinical study to comparatively evaluate the impact of Drawtex wound dressing against wound bioburden in moderately to highly exuding venous leg ulcers.
Detailed description
Each subject is expected to participate in this study for a period of four weeks or until reepithelialization, whichever occurs first. Subjects may participate for an additional period of four weeks or until reepithelialization, whichever occurs first: this it to be decided by the investigator and will be determined by the accessibility of the patient (physical location) and the suitability of the wound to further treatment. The maximum time period for the study is 8 weeks. The minimum time frame is at least 4 week, or until reepithelialization occurs.
Interventions
DEVICEDrawtex dressing
The dressing is indicated for moderately to heavily exuding wounds such as venous leg ulcers
Sponsors
Beier Drawtex Healthcare, (PTY). Ltd
Southwest Regional Wound Care Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Subject \> 18 years. * Subject is attending weekly office visits at SW Wound Care Center as an out-patient. * Subject has a moderately to highly exudative venous leg ulcer that would be indicated for treatment with Drawtex * Subject or is informed about the trial, understands its nature of the study and provides written informed consent prior to study enrollment. * Subject is willing and able to comply with all specified care and visit requirements
Exclusion criteria
* Subject has a lesion that does not meet the inclusion criteria. * Subject refuses to participate in the study. * Subject already participates in the this study with one wound (only one wound per subject is allowed) * Subject has known sensitivity to the trial product or any of its compounds. * Subject is expected to be non-compliant. * Subject's lesion is a primary skin cancer. * Subject's lesion is the manifestation of a metastasis. * Subject is pregnant.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To investigate the impact of Drawtex on wound surface bioburden. | 2 years | The dressing is indicated for moderately to heavily exuding wounds such as venous leg ulcers.• The safety of Drawtex will be measured by the number and type of any adverse events. Patient's tolerance and acceptance of the different dressings |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Tolerance | 2 years | To further investigate whether Drawtex * Will have an overall benefit on the wound healing process. * Patient's tolerance and acceptance of the dressings. The overall effect on wound healing, as expressed by percentages of necrosis, slough, granulation and/or epithelium at the wound surface. * Condition of periwound skin * Mobility restrictions, related to the dressing * The number of dressings per dressing change, the number of dressing changes and the amount of nursing time involved |
Countries
United States
Outcome results
None listed